Kernal Biologics develops mRNA-based cancer therapeutics using a proprietary mRNA 2.0 platform engineered to evade immune detection and home in on cancer cells. The company aims to improve patient survival and quality of life by delivering onco-selective treatments while minimizing common side effects. It also licenses portions of its technology to global pharma and biotech companies for non-oncology applications to help fund internal programs. Management is led by co-founder and CEO Yusuf Erkul, M.D., and co-founder and President Burak Yilmaz, M.S. The company recently added Manfred Kraus, Ph.D., as Vice President of Research and Development. Financially, Kernal closed a $25M Series A to advance its programs. Use of proceeds includes extending the mRNA 2.0 platform and supporting an IND filing for immuno-oncology candidate KR-335.

Total raised

$25M

Funding rounds

1

Latest round

Series A

Latest activity

Jul 2022